Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: GlobeNewswire
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment patterns and their impact on gastrointestinal (GI) related healthcare resource utilization (HCRU), has been accepted as a poster presentation at the upcoming Digestive Disease Week Conference (DDW), to be held May 2-5, 2026, in Chicago. Information regarding DDW can be found here. Patient Factors Associated with Irritable Bowel Syndrome with Constipation (IBS-C) Treatment ChangesAuthors: Alan Fossa, Kyle Staller, Lavanya Viswanathan, Asma Khapra, Luisa ScottPoster: Sa1729Display Time: May 2, 2026, 12:30 - 1:30 PM CT In addition to the poster presentation during DDW, Ardelyx is sponsoring a Product The
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal OfficerGlobeNewswire
- Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswire
- Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings? [Yahoo! Finance]Yahoo! Finance
- Ardelyx CMO Appointment Tests Growth Plans For Tenapanor Based Therapies [Yahoo! Finance]Yahoo! Finance
- Ardelyx President and CEO Sells 41,000 Shares for $243,000 [Yahoo! Finance]Yahoo! Finance
ARDX
Earnings
- 2/19/26 - Miss
ARDX
Sec Filings
- 4/22/26 - Form 3
- 4/17/26 - Form 4
- 4/3/26 - Form 3
- ARDX's page on the SEC website